Related Experiment Video

Updated: Jul 15, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

10.1K

Caveolin-3: therapeutic target for diabetic myocardial ischemia/reperfusion injury

Xinyu Wen1, Yanwei Ji1, Hepeng Tang1

  • 1Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan City, China.

Molecular Medicine (Cambridge, Mass.)
|February 26, 2025
PubMed

Insights

Diabetic hearts suffer more from ischemia/reperfusion (I/R) injury due to impaired Caveolin-3 (Cav-3) protein. Restoring Cav-3 function offers a therapeutic target for diabetic myocardial I/R injury.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Diabetology

Background:

  • Myocardial ischemia/reperfusion (I/R) injury poses significant health risks, particularly in diabetic patients.
  • Diabetic hearts exhibit increased susceptibility to I/R injury, with limited efficacy of current treatments.
  • Caveolin-3 (Cav-3) is crucial for cardiomyocyte function and protection, but its expression is reduced in diabetes.

Purpose of the Study:

  • To review the role of Caveolin-3 (Cav-3) in diabetic myocardial I/R injury.
  • To highlight Cav-3's function as a signaling platform in cardiomyocytes.
  • To discuss therapeutic strategies targeting Cav-3 for diabetic I/R injury.

Main Methods:

  • Literature review of studies on myocardial I/R injury and diabetes.
  • Analysis of the role of Caveolin-3 in cardiomyocyte signaling and protection.
  • Evaluation of therapeutic potential of Cav-3 modulation.

Main Results:

  • Impaired Cav-3 expression in diabetic hearts exacerbates I/R injury.
  • Reduced Cav-3 compromises protective conditioning strategies in diabetic myocardium.
  • Cav-3 acts as a key signal integration and transduction element.

Conclusions:

  • Caveolin-3 dysfunction is a critical factor in diabetic myocardial I/R vulnerability.
  • Targeting Cav-3 presents a promising therapeutic avenue for I/R injury in diabetic patients.
  • Further research into Cav-3 modulation could improve treatment outcomes.
Keywords:
CardioprotectionCaveolin-3DiabetesMyocardial ischemia/Reperfusion injury

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

623
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

113

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...